Signal biomarkers
AssigneeOtago Innovation Limited
InventorsChristopher Joseph PERMBERTON, Arthur Mark RICHARDS
Life of this patent
Estimating the term…
Abstract
Diagnostics relating to C-type natriuretic and erythropoietin signal peptides and fragments, and kits, uses and applications therefore.
Claims18
An isolated binding agent selected from the group consisting of binding agents to SEQ ID NOS:1 and/or 4, an antigenic variant or fragment of SEQ ID NOS:1 and/or 4, binding agents to SEQ ID NOS:2, 3, 5, and/or 6, and an antigenic variant or fragment of SEQ ID NO:2, 3, 5, and/or 6, optionally wherein the isolated binding agent binds to an isolated peptide that comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 3, 5, and/or 6.
An isolated peptide, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 3, 5 and/or 6.
A method for predicting, diagnosing, or monitoring in a subject (i) a cardiac disorder, optionally a cardiac disorder is selected from the group consisting of acute coronary syndromes including AMI and angina, heart failure, vulnerable plaque, and vascular disease including atherosclerosis, or (ii) an acute and/or chronic renal disease, injury, or disorder, the method comprising:
- (a) measuring the level of EPOsp and/or CNPsp immunoreactivity, or an EPOsp and/or CNPsp, or an EPOsp and/or a CNPsp fragment in a biological sample from the subject, wherein the measuring optionally is performed within the first forty-eight hours, twenty-four hours, twelve hours, six hours, four hours, two hours, one hour, or 30 minutes of onset of, or clinical presentation with, the cardiac or renal disease or disorder, optionally using an assay selected from mass spectroscopy (including SELDI, ESI, MALDI or FTIC), RIA, ELISA, fluoroimmunoassay, immunofluorometric assay, and immunoradiometric assay;
- and
- (b) comparing the level of said EPOsp and/or CNPsp immunoreactivity or said EPOsp and/or said CNPsp peptide or fragment with the level from a control,
- wherein a measured level of EPOsp and/or CNPsp immunoreactivity, an EPOsp and/or CNPsp, or an EPOsp fragment and/or a CNPsp fragment thereof higher than the control level is indicative of said cardiac disorder.
A use, wherein the use is selected from the group consisting of (i) a use of a peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 3, 5 and/or 6 in the preparation of an antibody and (ii) a use of a binding agent for EPOsp and/or CNPsp immunoreactivity, an EPOsp and/or CNPsp, or an EPOsp and/or CNPsp fragment for the manufacture of a kit for the assay for assessing a biological event or disorder in a subject.
A kit for predicting, diagnosing, or monitoring an acute cardiac disorder, comprising a binding agent directed to an EPOsp and/or CNPsp or fragment thereof;
- and optionally comprising instructions for predicting, diagnosing or monitoring said acute cardiac disorder in a subject within six or four hours of onset, or clinical presentation, from the level of an EPOsp and/or CNPsp, or fragment thereof, measured in a biological sample obtained within six or four hours of onset or clinical presentation with ACS.
Dependencies are inferred from the claim text.